Search results for "immunosuppressive agent"

showing 10 items of 282 documents

The Programmed Death (PD)‐1/PD‐Ligand 1 Pathway Regulates Graft‐Versus‐Host‐Reactive CD8 T Cells After Liver Transplantation

2008

Acute graft-versus-host disease (aGVHD) is a life-threatening complication after solid-organ transplantation, which is mediated by host-reactive donor T cells emigrating from the allograft. We report on two liver transplant recipients who developed an almost complete donor chimerism in peripheral blood and bone marrow-infiltrating T cells during aGVHD. By analyzing these T cells directly ex vivo, we found that they died by apoptosis over time without evidence of rejection by host T cells. The host-versus-donor reactivity was selectively impaired, as anti-third-party and antiviral T cells were still detectable in the host repertoire. These findings support the acquired donor-specific allotol…

CD4-Positive T-LymphocytesMaleCell TransplantationProgrammed Cell Death 1 ReceptorGraft vs Host DiseaseCD8-Positive T-LymphocytesTCIRG1MiceInterleukin 21Immune systemAntigenAntigens CDAnimalsHumansImmunology and AllergyCytotoxic T cellMedicinePharmacology (medical)IL-2 receptorMice KnockoutTransplantationbusiness.industryInterleukin-2 Receptor alpha SubunitForkhead Transcription FactorsMiddle AgedLiver TransplantationTransplantationsurgical procedures operativeGene Expression RegulationAntigens SurfaceImmunologyInterleukin 12Apoptosis Regulatory ProteinsbusinessImmunosuppressive AgentsAmerican Journal of Transplantation
researchProduct

Angioimmunoblastic T-cell lymphoma

2008

Angioimmunoblastic T-cell lymphoma (AITL) is a rare and aggressive neoplasm clinically characterized by sudden onset of constitutional symptoms, lymphadenopathy, hepatosplenomegaly, frequent autoimmune phenomena, particularly hemolytic anemia and thrombocytopenia, and polyclonal hypergammaglobulinemia. The lymph node histological picture is also distinctive, constituted by a polymorphic infiltrate, a marked proliferation of high endothelial venules, and a dense meshwork of dentritic cells. The neoplastic CD4+ T-cells represent a minority of the lymph node cell population; its detection is facilitated by the aberrant expression of CD10. Almost all cases arbor an EBV infected B-cell populatio…

CD4-Positive T-LymphocytesMaleEpstein-Barr Virus InfectionsPathologyAutologous transplantHerpesvirus 4 HumanHepatosplenomegalyImmunosuppressive AgentEpstein-Barr Virus InfectionHypergammaglobulinemiaLymph nodeNon-Hodgkin lymphomaAngioimmunoblastic lymphomaB-Lymphocyteseducation.field_of_studyB-LymphocyteLymph NodeHematologyThalidomideSurvival RateTransplantation Autologoumedicine.anatomical_structureOncologyCD4-Positive T-LymphocyteFemaleNeprilysinmedicine.symptomImmunosuppressive AgentsHumanmedicine.medical_specialtyAngioimmunoblastic T-cell lymphomaPopulationHigh endothelial venulesDendritic CellLymphoma T-CellTransplantation AutologousmedicineHumanseducationCell Proliferationbusiness.industryPeripheral T-cell lymphomaDendritic Cellsmedicine.diseasePeripheral T-cell lymphomaLymphomaTransplantationImmunologyLymph NodesGeriatrics and GerontologybusinessStem Cell Transplantation
researchProduct

Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for methot…

1999

SUMMARYImmunosuppressive therapy with methotrexate (MTX) has been established as effective treatment for patients with rheumatoid arthritis. To analyse the therapeutic potential and mechanisms of action of MTX, we determined serum cytokine levels and cytokine production by splenic T cells and macrophages in untreated and MTX-treated mice. Furthermore, we assessed the role of MTX in a murine model of experimental arthritis induced by collagen type II (CIA). MTX reduced spontaneous and IL-15-induced tumour necrosis factor (TNF) production by splenic T cells but not by macrophages from healthy mice in vitro in a dose-dependent manner. In contrast, interferon-gamma (IFN-γ) production was less s…

CD4-Positive T-LymphocytesMalemusculoskeletal diseasesT-Lymphocytesmedicine.medical_treatmentImmunologyArthritisMice TransgenicSpleenInterferon-gammaMiceImmune systemAnimalsImmunology and AllergyMedicineheterocyclic compoundsInterferon gammaskin and connective tissue diseasesInterleukin 4Interleukin-15Mice KnockoutMice Inbred BALB CInterleukin-6Tumor Necrosis Factor-alphabusiness.industryMacrophagesOriginal ArticlesImmunotherapymedicine.diseaseArthritis ExperimentalMethotrexatemedicine.anatomical_structureCytokineMice Inbred DBAImmunologyCytokinesTumor necrosis factor alphaCollagenInterleukin-4businessImmunosuppressive AgentsSpleenmedicine.drug
researchProduct

Mycophenolate mofetil for treatment of active inflammatory bowel disease. Clinical and immunological studies.

1998

CD4-Positive T-Lymphocytesmedicine.medical_specialtybusiness.industryTumor Necrosis Factor-alphaGeneral NeuroscienceMacrophagesT-LymphocytesMycophenolic AcidMycophenolatemedicine.diseaseInflammatory Bowel DiseasesInflammatory bowel diseaseGastroenterologyGeneral Biochemistry Genetics and Molecular BiologyHistory and Philosophy of ScienceInternal medicinemedicineHumansbusinessCells CulturedImmunosuppressive AgentsAnnals of the New York Academy of Sciences
researchProduct

Cachexia: a therapeutic approach beyond cytokine antagonism

2002

Cachexia is seen in a number of chronic diseases, and it is always associated with a poor prognosis. Irrespective of etiology, the development of cachexia appears to share a common pathophysiological pathway. This includes induction of proteasome-dependent myofibril-degradation, which is thought to be secondary to stimulation by enhanced levels of pro-inflammatory cytokines. Elevation of tumor necrosis factor-alpha (TNFalpha) and other plasma cytokines has been demonstrated in many conditions associated with cachexia. Despite improved pathophysiological understanding, a specific treatment for cachexia has not yet been established. Whilst direct TNFalpha antagonism has therapeutic appeal, th…

CachexiaTumor Necrosis Factor-alphabusiness.industrymedicine.medical_treatmentNF-kappa BImmunosuppressionNF-κBmedicine.diseaseCachexiaTranscription Factor AP-1PathogenesisTherapeutic approachchemistry.chemical_compoundTreatment OutcomeCytokinechemistryImmunologyCytokinesHumansMedicineTumor necrosis factor alphaCardiology and Cardiovascular MedicineAntagonismbusinessImmunosuppressive AgentsInternational Journal of Cardiology
researchProduct

Advances in haploidentical stem cell transplantation for hematologic malignancies

2016

One of the most important advances in allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the use of alternative donors and cell sources, such as haploidentical transplants (haplo-HSCT) from family donors. Several approaches have been developed to overcome the challenging bidirectional alloreactivity. We discuss these approaches, including ex vivo T-cell-depleted grafts with megadose of CD34(+) cells, not requiring immunosuppression after allogeneic transplantation for graft-versus-host disease (GVHD) prophylaxis, and other strategies using unmanipulated T-cell-replete grafts with intensive immunosuppression or post-transplantation cyclophosphamide to minimize the GVHD. We als…

Cancer ResearchAllogeneic transplantationmedicine.medical_treatmentGraft vs Host DiseaseContext (language use)Hematopoietic stem cell transplantationT-Lymphocytes RegulatoryLymphocyte DepletionDonor Selection03 medical and health sciences0302 clinical medicineReceptors KIRHLA AntigensmedicineHumansCyclophosphamideDonor selectionbusiness.industryHistocompatibility TestingHematopoietic Stem Cell TransplantationImmunosuppressionHematologyAllograftsTransplantationTreatment Outcomesurgical procedures operativeClinical Trials Phase III as TopicOncologyHematologic Neoplasms030220 oncology & carcinogenesisTransplantation HaploidenticalImmunologyStem cellUnrelated DonorsbusinessImmunosuppressive AgentsEx vivo030215 immunologyLeukemia & Lymphoma
researchProduct

Comparative activity of idarubicin and idarubicinol in combination with cyclosporin A in multidrug-resistant leukemia cells

1996

4-Demethoxydaunorubicin (idarubicin, IDA) is an anthracycline that has shown good cytotoxic activity in vitro against tumor cell lines displaying the multidrug-resistant (MDR) phenotype. IDA is converted in the liver into idarubicinol (2HIDA) and, in this form, seems to exert its antitumoral activity in vivo. Recent studies have shown that 2HIDA has tumoricidal activity similar to that of the parent drug when tested in vitro in sensitive neoplastic cells. In this work we compared in vitro the effects of IDA and 2HIDA used alone and in combination with 2 microM cyclosporin A (CyA) in the MDR leukemic cell lines FLCR and K562R and in their sensitive parent cell lines FLC and K562. IDA and 2HI…

Cancer ResearchAnthracyclineAntineoplastic AgentsPharmacologyBiologyToxicologyIn vivohemic and lymphatic diseasesCyclosporin aAntineoplastic Combined Chemotherapy ProtocolsTumor Cells CulturedmedicineCytotoxic T cellIdarubicinPharmacology (medical)PharmacologyAntibiotics AntineoplasticDaunorubicinnutritional and metabolic diseasesFlow CytometryDrug Resistance MultipleIn vitroMultiple drug resistanceOncologyCell cultureCyclosporineIdarubicinImmunosuppressive Agentsmedicine.drugCancer Chemotherapy and Pharmacology
researchProduct

Bovine seminal ribonuclease is cytotoxic for both malignant and normal telomerase-positive cells

2005

Bovine seminal-ribonuclease (BS-RNase) is a member of the 'ribonucleases with special biological actions' family since it possesses specific anti-tumour, anti-spermatogenic and embryotoxic activities and exerts an immunosuppressive effect on T lymphocytes. In previous studies it was demonstrated that BS-RNase induced apoptosis in proliferating, malignant and normal cells and that telomerase activity loss also caused apoptotic death in neoplastic cells. Since an obvious relationship between cell proliferation and telomerase activity exists, the aim of this work was to study if the pro-apoptotic cytotoxic action exerted by BS-RNase on proliferating malignant cells (HT29) and proliferating nor…

Cancer ResearchTelomeraseTime FactorsT-LymphocytesCellular differentiationCytotoxicityBlotting WesternDown-RegulationTetrazolium SaltsAntineoplastic AgentsApoptosisEnzyme-Linked Immunosorbent AssayBiologyHT29 CellsCell Line TumorEndoribonucleasesAnimalsHumansCytotoxic T cellTelomerase reverse transcriptaseLymphocytesRNA MessengerTelomeraseBovine seminal-ribonuclease; Cytotoxicity; HTR; Nucleolar localization; TelomeraseCell ProliferationReverse Transcriptase Polymerase Chain ReactionCell growthCell DifferentiationCell cycleNucleolar localizationMolecular biologyThiazolesBovine seminal-ribonucleaseMicroscopy FluorescenceOncologyCell cultureLeukocytes MononuclearMicroscopy Electron ScanningRNACattleHTRCell NucleolusImmunosuppressive Agents
researchProduct

A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway

2014

CD4(+)CD25(+) regulatory T cells (Tregs) represent a specialized subpopulation of T cells, which are essential for maintaining peripheral tolerance and preventing autoimmunity. The immunomodulatory effects of Tregs depend on their activation status. Here we show that, in contrast to conventional anti-CD4 monoclonal antibodies (mAbs), the humanized CD4-specific monoclonal antibody tregalizumab (BT-061) is able to selectively activate the suppressive properties of Tregs in vitro. BT-061 activates Tregs by binding to CD4 and activation of signaling downstream pathways. The specific functionality of BT-061 may be explained by the recognition of a unique, conformational epitope on domain 2 of th…

Cell signalingProtein Conformationmedicine.drug_classMolecular Sequence DataImmunologyAntibodies Monoclonal HumanizedCrystallography X-RayLymphocyte ActivationMonoclonal antibodyT-Lymphocytes RegulatoryEpitopeT-Lymphocyte SubsetsTransforming Growth Factor betamedicineHumansImmunology and Allergyddc:610Amino Acid SequenceIL-2 receptorPhosphorylationCells CulturedbiologyInterleukin-2 Receptor alpha SubunitAntibodies MonoclonalPeripheral toleranceCell BiologyTransforming growth factor betaMolecular biologyCell biologyCD4 Antigensbiology.proteinEpitopes B-LymphocyteSignal transductionImmunosuppressive AgentsProtein BindingSignal TransductionConformational epitopeImmunology & Cell Biology
researchProduct

Adalimumab vs Azathioprine in the Prevention of Postoperative Crohn's Disease Recurrence. A GETECCU Randomised Trial.

2017

Background and aims Postoperative recurrence of Crohn's disease [POR-CD] is almost certain if no prophylaxis is administered. Evidence for optimal treatment is lacking. Our aim was to compare the efficacy of adalimumab [ADA] and azathioprine [AZA] in this setting. Methods We performed a phase 3, 52-week, multicentre, randomised, superiority study [APPRECIA], in which patients with ileocolonic resection were randomised either to ADA 160-80-40 mg subcutaneously [SC] or AZA 2.5 mg/kg/day, both associated with metronidazole. The primary endpoint was endoscopic recurrence at 1 year [Rutgeerts i2b, i3, i4], as evaluated by a blinded central reader. Results We recruited 91 patients [median age 35.…

Crohn’s diseaseAdultMalemedicine.medical_specialtyAzathioprineGastroenterology03 medical and health sciences0302 clinical medicineCrohn DiseaseInternal medicineadalimumabAzathioprinemedicineClinical endpointAdalimumabSecondary PreventionHumansAdverse effectPostoperative CareCrohn's diseaseazathioprinebusiness.industryAdalimumabGastroenterologyGeneral Medicinemedicine.diseaseSurgeryDiscontinuationCrohn's diseaseMetronidazole030220 oncology & carcinogenesisUnselected population030211 gastroenterology & hepatologyFemalebusinessImmunosuppressive Agentsmedicine.drug
researchProduct